Understanding Antipsychotic Drug Tolerability

Abstract

Get full access to this article

View all access options for this article.

References

Duval

Goldman

. The new drugs (chlorpromazine & reserpine): Administrative aspects. 1956. Psychiatr Serv 2000; 51: 327–31.

DeVane

. No mourning for the conventional antipsychotics: The dawn of the atypical agents. Ann Pharmacother 1999; 33: 107–8.

Geddes

Freemantle

Harrison

Bebbington

. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6.

Chakos

Lieberman

Hoffman

Bradford

Shietman

. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia; a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518–26.

Schillevoort

de Boer

Herings

Roos

Jansen

Leufkens

. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001; 35: 1517–22.

Kapur

Remington

. Atypical antipsychotics. BMJ 2000; 321: 1360–1.

Casey

. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10 (suppl 3):105–14.

Voruganti

Cortese

Oyewumi

Cernovsky

Zirul

Awad

. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–45.

Stannilard

Taylor

. Tolerability of atypical antipsychotics. Drug Saf 2000; 22: 195–214.